Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Amphastar Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221 (market cap $29.60B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $868.62M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 34.1× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYAMPH
Market Cap
$29.60B$868.62M
Sector
HealthHealth
52-Week High
$491.22$30.81
52-Week Low
$205.48$16.87
Enterprise Value
$27.56B$1.27B

Returns comparison

Trailing returns across standard periods

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH